Reaction
Duodenal Perforation reporting signals
As of the last recalculation, Duodenal Perforation appears in 960 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is LENVATINIB (PRR 26.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Lenvatinib | 39 | 26.8 | 26.9 |
| Bevacizumab | 118 | 23.4 | 23.4 |
| Indomethacin | 11 | 18.2 | 18.2 |
| Pyrazinamide | 7 | 16.3 | 16.3 |
| Granisetron Hydrochloride | 7 | 14.6 | 14.6 |
| Fluorouracil | 49 | 14.4 | 14.4 |
| Pemetrexed | 14 | 14.4 | 14.4 |
| Fluorouracil Cream, 0.5% | 48 | 14.3 | 14.3 |
| Posaconazole Delayed-Release | 7 | 13.9 | 13.9 |
| Dexamethasone Sodium Phosphate | 6 | 12.9 | 12.9 |
| Pembrolizumab | 58 | 12.7 | 12.7 |
| Atezolizumab | 22 | 12.5 | 12.6 |
| Regorafenib | 6 | 11.3 | 11.3 |
| Pemetrexed Disodium | 19 | 11.0 | 11.0 |
| Pertuzumab | 13 | 10.5 | 10.5 |
| Paclitaxel | 42 | 9.6 | 9.6 |
| Oxaliplatin | 31 | 9.3 | 9.3 |
| Paclitaxel (Aibumin-Bound) | 34 | 9.3 | 9.3 |
| Gefitinib | 3 | 7.2 | 7.2 |
| Cetuximab | 10 | 7.0 | 7.0 |
| Encorafenib | 3 | 6.6 | 6.6 |